Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations
Identifieur interne : 000123 ( Istex/Corpus ); précédent : 000122; suivant : 000124Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations
Auteurs : Albert F. G. Leentjens ; Kathy Dujardin ; Laura Marsh ; Pablo Martinez-Martin ; Irene H. Richard ; Sergio E. Starkstein ; Daniel Weintraub ; Cristina Sampaio ; Werner Poewe ; Oliver Rascol ; Glenn T. Stebbins ; Christopher G. GoetzSource :
- Movement Disorders [ 0885-3185 ] ; 2008-10-30.
English descriptors
- KwdEn :
Abstract
Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (AI), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith‐Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as “recommended” to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of “Suggested.” Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22229
Links to Exploration step
ISTEX:B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation><mods:affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation><mods:affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, Australia</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22229</idno><idno type="url">https://api.istex.fr/document/B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000123</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation><mods:affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation><mods:affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, Australia</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-10-30">2008-10-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2004">2004</biblScope><biblScope unit="page" to="2014">2014</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0</idno><idno type="DOI">10.1002/mds.22229</idno><idno type="ArticleID">MDS22229</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>anhedonia</term><term>apathy</term><term>clinimetrics</term><term>depression</term><term>psychometrics</term><term>rating scales</term><term>reliability</term><term>validity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (AI), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith‐Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as “recommended” to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of “Suggested.” Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Albert F.G. Leentjens MD, PhD</name><affiliations><json:string>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</json:string></affiliations></json:item><json:item><name>Kathy Dujardin PhD</name><affiliations><json:string>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Laura Marsh MD</name><affiliations><json:string>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</json:string><json:string>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>Pablo Martinez‐Martin MD, PhD</name><affiliations><json:string>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Irene H. Richard MD</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</json:string><json:string>Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Sergio E. Starkstein MD</name><affiliations><json:string>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, Australia</json:string></affiliations></json:item><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD</name><affiliations><json:string>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Portugal</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University Hospital, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Oliver Rascol MD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins PhD</name><affiliations><json:string>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>apathy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anhedonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinimetrics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychometrics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rating scales</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>validity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>reliability</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (AI), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith‐Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as “recommended” to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of “Suggested.” Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>7.976</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1616</abstractCharCount><pdfWordCount>6788</pdfWordCount><pdfCharCount>42319</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>248</abstractWordCount></qualityIndicators><title>Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>11</total><last>2014</last><first>2004</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.22229</json:string></doi><id>B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: K. Dujardin has been involved in the development of the Lille Apathy Rating Scale, and S. Starkstein has been involved in the development of the Apathy Scale. None of the authors have any financial interest in the use of any of the scales included in this reviews.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title><author><persName><forename type="first">Albert F.G.</forename><surname>Leentjens</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Psychiatry, Maastricht University Hospital, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</p></note><affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</affiliation></author><author><persName><forename type="first">Kathy</forename><surname>Dujardin</surname><roleName type="degree">PhD</roleName></persName><affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Marsh</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation></author><author><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Irene H.</forename><surname>Richard</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation><affiliation>Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Sergio E.</forename><surname>Starkstein</surname><roleName type="degree">MD</roleName></persName><affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, Australia</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname><roleName type="degree">MD</roleName></persName><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Portugal</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Oliver</forename><surname>Rascol</surname><roleName type="degree">MD</roleName></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</affiliation></author><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-10-30"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2004">2004</biblScope><biblScope unit="page" to="2014">2014</biblScope></imprint></monogr><idno type="istex">B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0</idno><idno type="DOI">10.1002/mds.22229</idno><idno type="ArticleID">MDS22229</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (AI), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith‐Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as “recommended” to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of “Suggested.” Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>apathy</term></item><item><term>anhedonia</term></item><item><term>depression</term></item><item><term>Parkinson's disease</term></item><item><term>clinimetrics</term></item><item><term>psychometrics</term></item><item><term>rating scales</term></item><item><term>validity</term></item><item><term>reliability</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-02-11">Received</change><change when="2008-06-20">Registration</change><change when="2008-10-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v23:14</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2008-10-30">30 October 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22229</doi><idGroup><id type="unit" value="MDS22229"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-02-11"></event><event type="manuscriptRevised" date="2008-06-02"></event><event type="manuscriptAccepted" date="2008-06-20"></event><event type="publishedOnlineEarlyUnpaginated" date="2008-08-16"></event><event type="firstOnline" date="2008-08-16"></event><event type="publishedOnlineFinalForm" date="2008-10-27"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2004</numbering><numbering type="pageLast">2014</numbering></numberingGroup><correspondenceTo>Department of Psychiatry, Maastricht University Hospital, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22229.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="40"></count><count type="wordTotal" number="8115"></count></countGroup><titleGroup><title type="main" xml:lang="en">Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations<link href="#fn7"></link></title><title type="short" xml:lang="en">Apathy Scales in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Albert F.G.</givenNames><familyName>Leentjens</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>a.leentjens@np.unimaas.nl</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Kathy</givenNames><familyName>Dujardin</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Laura</givenNames><familyName>Marsh</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af6 #af7"><personName><givenNames>Irene H.</givenNames><familyName>Richard</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Sergio E.</givenNames><familyName>Starkstein</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Oliver</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="NL" type="organization"><unparsedAffiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="ES" type="organization"><unparsedAffiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="AU" type="organization"><unparsedAffiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">apathy</keyword><keyword xml:id="kwd2">anhedonia</keyword><keyword xml:id="kwd3">depression</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">clinimetrics</keyword><keyword xml:id="kwd6">psychometrics</keyword><keyword xml:id="kwd7">rating scales</keyword><keyword xml:id="kwd8">validity</keyword><keyword xml:id="kwd9">reliability</keyword></keywordGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22229:mds_22229_sm_SuppInfo"></mediaResource><caption>Supplementary material: Scale reviews</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (AI), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith‐Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as “recommended” to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of “Suggested.” Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn7"><p>Potential conflict of interest: K. Dujardin has been involved in the development of the Lille Apathy Rating Scale, and S. Starkstein has been involved in the development of the Apathy Scale. None of the authors have any financial interest in the use of any of the scales included in this reviews.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Apathy Scales in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations</title></titleInfo><name type="personal"><namePart type="given">Albert F.G.</namePart><namePart type="family">Leentjens</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, Maastricht University Hospital, Maastricht, The Netherlands</affiliation><description>Correspondence: Department of Psychiatry, Maastricht University Hospital, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kathy</namePart><namePart type="family">Dujardin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Marsh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation><affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene H.</namePart><namePart type="family">Richard</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation><affiliation>Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sergio E.</namePart><namePart type="family">Starkstein</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Western Australia, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oliver</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-10-30</dateIssued><dateCaptured encoding="w3cdtf">2008-02-11</dateCaptured><dateValid encoding="w3cdtf">2008-06-20</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">40</extent><extent unit="words">8115</extent></physicalDescription><abstract lang="en">Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (AI), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith‐Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as “recommended” to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of “Suggested.” Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions. © 2008 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: K. Dujardin has been involved in the development of the Lille Apathy Rating Scale, and S. Starkstein has been involved in the development of the Apathy Scale. None of the authors have any financial interest in the use of any of the scales included in this reviews.</note><subject lang="en"><genre>Keywords</genre><topic>apathy</topic><topic>anhedonia</topic><topic>depression</topic><topic>Parkinson's disease</topic><topic>clinimetrics</topic><topic>psychometrics</topic><topic>rating scales</topic><topic>validity</topic><topic>reliability</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supplementary material: Scale reviews - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2004</start><end>2014</end><total>11</total></extent></part></relatedItem><identifier type="istex">B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0</identifier><identifier type="DOI">10.1002/mds.22229</identifier><identifier type="ArticleID">MDS22229</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000123 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000123 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B53E9AA078ACC8EF33F7B2B871365AF3EB8FB1E0
|texte= Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |